5-Hydroxytryptophan Dl- Alfalfa Avena Sativa Flowe

證據等級: L5

預測適應症: 0 個

Multi-Component Serotonergic Homeopathic Formulation: Evaluation Incomplete — Insufficient Data for Repurposing Assessment

One-Sentence Summary

This Evidence Pack describes a complex 13-component formulation containing serotonergic precursors (5-HTP, serotonin, tryptophan), herbal botanicals (alfalfa, avena sativa, salix alba, strychnos ignatii), homeopathic-origin ingredients (lachesis muta venom, sepia officinalis, sus scrofa pineal gland and thymus), and other biological components (salmonella typhi nosode, phosphoric acid). The TxGNN model returned no predicted indications for this candidate, which — combined with the complete absence of regulatory history, mechanism-of-action data, and safety records — means a full repurposing evaluation cannot be completed at this time. The recommended action is Hold pending resolution of multiple blocking data gaps.

Quick Overview

Item	Content
Original Indication	Unknown — no regulatory licenses on record
Predicted New Indication	None — TxGNN returned no predictions for this candidate
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only) — and even this is absent
US Market Status	Not marketed (0 licenses found)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN prediction is available for this candidate, so a standard mechanistic rationale cannot be constructed.

What can be observed from the ingredient list is that several components are pharmacologically related to the serotonergic system:

5-Hydroxytryptophan (5-HTP) is a direct precursor to serotonin and melatonin biosynthesis, commonly studied in depression, insomnia, fibromyalgia, and anxiety.
Tryptophan is the upstream amino acid in the same pathway.
Serotonin itself appears as a listed ingredient, suggesting the formulation may be intended for mood, sleep, or neuroendocrine modulation.

The remaining ingredients — lachesis muta venom, sepia officinalis juice, strychnos ignatii seed, sus scrofa pineal gland, sus scrofa thymus, and salmonella typhi nosode — are characteristic of classical homeopathic preparations, where substances are used in highly diluted form. These do not have established pharmacological mechanisms in the conventional sense.

Because the formulation is heterogeneous, pharmacologically complex, and not mapped to a DrugBank ID, the TxGNN knowledge graph could not identify a repurposing candidate. Without a standardised drug entity, graph-based prediction is not feasible.

Currently, detailed mechanism of action data is not available. Based on known information, this product contains ingredients associated with mood and sleep regulation, but its overall pharmacological profile as a formulation is undescribed.

Clinical Trial Evidence

Currently no related clinical trials registered for this multi-component formulation as a whole entity.

Note: Individual components such as 5-HTP and tryptophan do have clinical trial records as standalone compounds. If the evaluation is reframed around a specific active component, relevant trial evidence can be retrieved.

Literature Evidence

Currently no related literature available for this combined formulation as a unified drug entity.

Note: Substantial literature exists for individual ingredients (e.g., 5-HTP in depression and fibromyalgia; salix alba in pain; avena sativa in anxiety). A component-specific reassessment is recommended.

US Market Information

No US regulatory licenses found for this formulation. The product is not marketed in the United States under any identified NDA or registration.

Safety Considerations

Please refer to the package insert for safety information. No safety data was retrievable for this formulation:

Key warnings: not available
Contraindications: not available
Drug-drug interactions: no interactions found in database query

Practical caution: Formulations containing serotonergic precursors (5-HTP, serotonin, tryptophan) carry a theoretical risk of serotonin syndrome, particularly when co-administered with SSRIs, MAOIs, SNRIs, or triptans. This should be flagged as a priority safety concern even in the absence of formal DDI data.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack contains no TxGNN predictions, no regulatory history, no mechanism-of-action data, and no retrievable safety records. The drug entity itself could not be resolved to a DrugBank ID, which is a prerequisite for knowledge-graph-based repurposing analysis. Proceeding without these foundational data elements would produce unreliable outputs.

To proceed, the following is needed:

[Blocking] Resolve drug identity: Determine whether this formulation is a registered product under a single brand name or a research compound. Assign a DrugBank ID to at least the primary active ingredient (5-HTP recommended as anchor).
[Blocking] Obtain package insert or prescribing information: Required for safety pre-screening (warnings, contraindications, serotonin syndrome risk).
[High] Define scope of repurposing target: Decide whether TxGNN should be run on (a) the whole formulation, (b) the primary active component (5-HTP), or (c) each ingredient separately.
[High] Retrieve MOA data from DrugBank: The DrugBank query returned 1 result — confirm which ingredient was matched and extract mechanism data.
[Medium] Clarify regulatory classification: Determine whether this product is classified as a pharmaceutical drug, dietary supplement, or homeopathic preparation in the target market, as this affects regulatory pathway selection.
[Medium] Assess serotonin syndrome risk profile: Given the serotonergic nature of 5-HTP, tryptophan, and serotonin as ingredients, a prospective DDI review for these components specifically is advised before any clinical application.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.